Somatostatin receptor Inhibitors
7 drugsAbout Somatostatin receptor
The Somatostatin receptor (SSTR) is a GPCR that mediates the effects of somatostatin, regulating various physiological processes. SSTR activation modulates hormone release and cell growth. It is a valuable drug target implicated in a variety of therapeutic areas.
Genetic evidence offers moderate support for SSTR2 as a therapeutic target, with associations to pneumonitis and smoking initiation (score 0.51). Colocalization studies show strong eQTL/pQTL signals (max H4: 0.99). This suggests potential for genetically informed drug development.
SSTR is targeted by 6 FDA-approved small molecule drugs, including OCTREOTIDE ACETATE, SANDOSTATIN LAR, and MYCAPSSA. These drugs are used to treat a range of conditions, with approvals spanning from 1998 to 2024.
Somatostatin receptor Genetic Evidence Moderate
Genetic evidence provides moderate support for SSTR2, with a max score of 0.51 linked to pneumonitis and smoking initiation.
Further investigation of the genetic links to pneumonitis and smoking initiation may reveal novel therapeutic opportunities.
Evidence Across Diseases
4 totalGWAS and other genetic studies link SSTR2 to 4 diseases.
🔗 Colocalization Evidence 3 strong
max H4: 0.99eQTL/pQTL signals for SSTR2 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top Somatostatin receptor Drugs
Five companies have approved SSTR-targeting drugs, including WEST-WARD PHARMS INT, IPSEN PHARMA, and Novartis.
The presence of multiple players suggests a competitive market, requiring a differentiated strategy for new entrants.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| OCTREOTIDE ACETATE PRESERVATIVE FREE | WOCKHARDT USA | 2005 | 5 |
| OCTREOTIDE ACETATE | Fresenius Kabi | 2005 | 3 |
| LANREOTIDE ACETATE | AMNEAL | 2021 | 3 |
| MYCAPSSA | CHIESI | 2020 | 1 |
Somatostatin receptor Drug Modality Landscape
Modalities
Routes of Administration
Somatostatin receptor is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Somatostatin receptor Clinical Trials 110 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Somatostatin receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 26 | 17 | 6 | 2 | 74% |
| Phase 2 | 39 | 24 | 10 | 5 | 71% |
| Phase 3 | 30 | 16 | 3 | 11 | 84% |
| Phase 4 | 15 | 9 | 4 | 2 | 69% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Somatostatin receptor Drug Approval Timeline (1998 - 2024)
The first SSTR-targeting drug was approved in 1998, with the most recent approval in 2024.
The continued approvals indicate sustained interest, but also suggest increasing market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 7 companies competing
- • Market share by company
Full Drug Portfolio
- • All 7 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 7-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 72 (22 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Somatostatin receptor. A trial counts if an approved drug acting on Somatostatin receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.